Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000996766 | SCV001151680 | uncertain significance | not provided | 2018-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002549950 | SCV003279273 | uncertain significance | Deficiency of alpha-mannosidase | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 60 of the MAN2B1 protein (p.Pro60Leu). This variant is present in population databases (rs145163643, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with MAN2B1-related conditions. ClinVar contains an entry for this variant (Variation ID: 808457). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002549949 | SCV003592537 | uncertain significance | Inborn genetic diseases | 2021-10-27 | criteria provided, single submitter | clinical testing | The c.179C>T (p.P60L) alteration is located in exon 2 (coding exon 2) of the MAN2B1 gene. This alteration results from a C to T substitution at nucleotide position 179, causing the proline (P) at amino acid position 60 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |